ESGBERT/base_data · Datasets at Hugging Face

sentence stringlengths 1 23.5k ⌀
Through decreased our emissions intensity by 12.7 percent compared to our 2012 baseline.
Total energy consumption was flat compared to improved by 0.7 percent.
Since largest energy-consuming sites—representing nearly 88 percent of our total energy consumption—increased production, in turn increasing their overall energy use per square foot of space.
In combined heat and power system at our Puerto Rico facility.
Since then, Lilly has completed initial design, with major construction expected to begin in 2019.
This project is expected to result in roughly $and approximately 15 to 20 percent reduction in GHG emissions for our Puerto Rico facility.
We also operate combined heat and power systems in Kinsale, Ireland; Sesto, Italy; and Speke, England.
Renewable Energy We will continue to evaluate further use of renewable energy to diversify our energy sources, decrease our GHG emissions, and lessen our energy use intensity over time.
We are members of the Rocky Mountain Institute’s Business Renewables Center and are currently evaluating the feasibility of incorporating more renewable energy sources.
WATER USE AND WASTEWATER Manufacturing operations account for the majority of the water used by Lilly.
In CDP’s water program, above the average for Biotech, Health Care and Pharmaceutical sector rankings.
In phosphorus emissions in our wastewater discharge by 15 percent by 2020, as compared to our 2014 baseline.
In our total wastewater phosphorus emissions declined to approximately 83 metric tonnes, a 34.4 percent decrease from 2014.
With regard to our goal progress, we have successfully surpassed our reduction goal at the end of 2018.
As a result, we are setting a stretch goal to reduce an additional of phosphorus emissions by 2020 using 2018 as the new baseline year.
We have significant source reduction projects planned, including phasing out and replacing selected cleaning agents with non-phosphorus- based alternatives.
In an increase of just under four percent from 2012, due primarily to production changes.
Lilly generates both nonhazardous and hazardous waste from its manufacturing processes.
In improvement in waste efficiency by 2020, as compared to our 2012 baseline.
We also aim to increase our recycling rate above below 10 percent of our total waste generated.
Lilly generated material directly reused) in 2018, representing a decrease of 28 percent compared to 2012, and a 30 percent decrease compared to 2017 amounts.
We were able to designate much of it as fertilizer.
With regard to progress toward our goal, we have successfully surpassed our improvement target, as our waste efficiency improved by 34 percent between 2012 and the end of 2018.
Our recycling rate increased in 47 percent in 2012, and we sent 21 percent of our waste to landfills, compared to 28 percent waste sent to landfill in 2012.
As we have successfully achieved the waste efficiency aspect of our we will focus primarily on achieving our recycling and waste-to-landfill targets.
OUR OPERATIONS We established the Energy, Waste and Water Reduction Fund in overall environmental impacts.
Since has invested more than $45.5 million in this fund, enabling the implementation of 174 projects, which all told, garnered more than $22 million in savings.
These projects collectively save more than one trillion BTUs of energy annually, avoiding more than tonnes of GHG emissions each year, measured as carbon dioxide equivalents (CO2e).
\| P A G E 1 Data may be revised compared to prior reports due to changes in calculation methodology and other factors.
emission factors for landfilled and land-applied waste, and assumes transportation related emissions only for certain land-applied organic waste types.
6 Data includes energy from combustion of coal, fuel oil, natural gas, and liquid propane. 7 Data includes energy from purchased electricity, steam, and chilled water.
regulatory actions or requirements (e.g., remediation activities where the water is not used for another purpose).
for the purpose of lowering the groundwater table(s) to maintain the physical and structural integrity of building foundations.
intake not included in other water intake subcategories.
sales and marketing offices unless they are co-located at a Lilly manufacturing or research facility.
that resulted in damage to the environment (i.e., human health, aquatic life, or wildlife) or a material event requiring reporting to the U.S. Securities and Exchange Commission.
This data includes that of Lilly’s former subsidiary, Elanco Animal Health, including the period immediately following Elanco’s IPO, approximately the fourth quarter of 2018.
A G E Supply Chain We rely on our suppliers—including those who supply us with materials for research and development, active pharmaceutical ingredients (APIs), and other contract manufacturers—to ensure the availability of our human and animal medicines.
This includes our ongoing work as part of the Pharmaceutical Supply Chain Initiative (PSCI), a non-profit business membership organization founded in Lilly as one of its inaugural members.
GOVERNANCE OF SUPPLY CHAIN AT LILLY PSCI, with its member companies, created and maintain the Pharmaceutical Industry Principles for Responsible Supply Chain Management (the PSCI Principles).
The PSCI Principles provide our industry with consistent supplier performance standards in the areas of ethics, labor, health and safety, the environment, and related management systems.
contract manufacturing services Lilly manufacturing procurement contracts ask that suppliers support the PSCI Principles and conform to the HSE expectations outlined in our Supplier Code of Business Conduct.
For more than a decade, Lilly HSE professionals have worked to assess and strengthen performance at the external research laboratories and contract manufacturing organizations (CMOs) with which we do business.
In conducted onsite audits at 33 CMO sites.
OTHER SUPPLIER EDUCATION AND ENGAGEMENT Lilly is an active PSCI member and our HSE professionals have led or participated in a number of PSCI sponsored webinars and in-country events.
In professionals participated in supplier capability training in China and India, building on work in 2017 conducting third-party auditor training.
A G E Packaging and Transportation We consider many factors in selecting product packaging, including sustainability considerations, such as materials use and recyclability.
Additionally, we have achieved GHG emission reductions by changing the shipping mode for some of our pharmaceutical products from air to ocean.
Another benefit of ocean shipping is an overall reduction in packaging used because less protective packaging is required during transport.
Lilly continues to work with customers, industry partners, and public health officials to address these product end-of-life issues.
Pharmaceuticals in the Environment (PiE) After they are used to improve human and animal health, medicines enter our natural environment through the normal biological processes of waste elimination.
Reports such as the World Health Organization’s Pharmaceuticals in Drinking Water (publications following an extensive, three-year joint study by the U.S. Environmental Protection Agency and U.S. Geological Survey on the presence of contaminants in drinking water and surface water have concluded that the concentrations of pharmaceuticals in drinking water are unlikely to have a direct impact on human health and aquatic life.
Due to the importance of PiE issues to Lilly and our stakeholders, we have established a PiE Governance Committee that reports to our executive-level Global HSE Committee.
\| P A G E pharmaceutical discharges from manufacturing sites, our Lilly Aquatic Exposure Guideline (LAEG) program.
residues in water, in collaboration with the U.S.
About Elanco Animal Health In September offering of Elanco, thereby making it an independently traded company.
Elanco provides comprehensive products and knowledge services to improve the health of food animals and pets in more than the world.
Antibiotics, including those manufactured by Elanco, are one way, but not the only way, that farmers keep their animals healthy.
Elanco Animal Health has updated its commitment to fighting antimicrobial resistance, which includes promoting responsible antibiotic use practices and policies while developing alternatives to medically important antibiotics (a subset of which include critically important antibiotics to human health).
ELANCO’S ANTIBIOTIC STEWARDSHIP PLAN The Antimicrobial Resistance Challenge, led by the Centers for Disease Control and Prevention (CDC) and U.S. Health and Human Services (HHS), is a yearlong effort to accelerate the fight against antimicrobial resistance with action across governments and industries.
Elanco’s commitment—outlined within the CDC’s Antimicrobial Resistance Challenge materials—is the next step in its eight-point antibiotic stewardship plan.
It is of utmost importance we address the complex challenge of antimicrobial resistance and preserve the effectiveness of medicines for people and animals.
Supporting the CDC and HHS effort is an important step in reaffirming our commitment to responsible antibiotic usage and veterinary oversight capacity around the world.
A G E Lilly focuses on creating a companywide culture where best-in-class safety practices are intuitively and consistently followed.
We have found that tracking leading—or predictive indicators—such as ergonomic risk, safety culture surveys, and vehicle safety training contributes greatly to our company safety culture.
Since we introduced our global safety goals in percent, equivalent to the prevention of hundreds of injuries and illnesses to Lilly employees across the globe.
In established new goals for the three occupational safety metrics we track: recordable injuries, lost-time injuries, and motor vehicle collision rate.
In influence behavior change and reduce company injury and illness rates.
We know that to reach our goals for safety performance, Lilly must continue to instill and promote a best-in-class safety culture.
While the most common work-related injuries are covered by our safety programs, we also have committed to systematically address infrequent but severe events, where the consequences can be potentially life-altering or fatal.
business processes In we created a global SIF team responsible for analyzing potential SIF events and precursors.
The SIF team analyzes event data, always focusing on reducing the probability of employees’ exposure to high-risk hazards.
2018 15% 2017 15% 2016 16% 2015 16% 2007 25% 1 Refers to non-motor vehicle injuries resulting in abrasion, contusion, and laceration.
\| P A G E Sales and Marketing Safety At Lilly, sales and marketing employees represent approximately 35 percent of our global workforce.
In motor vehicle safety program, HSEDirections, designed specifically for the thousands of Lilly employees who are on the road every day, visiting physicians, hospitals, clinics, and other customers.
effect it can have on individuals and their loved ones.
We work to foster a healthy, vibrant work environment, while also supporting our people in the important time that they spend at home, with their families, and in their communities.
At Lilly, we take a broad view of well-being that emphasizes multiple dimensions of each employee’s life.
While local cultures, regulations, and market dynamics influence our offerings in each country, our employee well-being strategy is global.
R A M A healthy workplace is one where employees and managers collaborate on processes to protect and promote the health, safety, and well-being of everyone.
Your social network can offer support, happiness, contentment, a sense of belonging, and can help during difficult times.
In the United States, our myBestLife program offers a set of tools and resources to help employees better manage their health, as well as identify those things that can help individuals live a healthier and more active life.
Lilly offers health plan coverage to employees and their eligible dependents, and our coverage for preventive health services go well beyond the requirements established under federal healthcare reform.
We partner with our food service vendors to offer a wide range of healthier dining choices and snacks—some of which are subsidized by Lilly.
We provide showers and bike racks for the more than by bicycle.
Other efforts to support our employees’ physical and emotional health in the United States include access to a dietitian, frequent fitness challenges, and a comprehensive employee assistance program.
Across the United States, we have also designated all sites smoke-free.
New parents are eligible for a generous parental leave, two on-site child development centers at corporate headquarters, back-up care options, and parenting education opportunities.
New mothers receive maternity leave benefits and access to lactation rooms.
We promote financial well-being through a variety of online financial tools and financial advisory programs, and we offer individual financial counseling on-site or by phone.
WELLNESS IN OUR INTERNATIONAL SITES Lilly affiliate sites around the world offer extensive wellness programs, aimed at providing a holistic approach to employee health, safety, and well-being.
These integrated programs feature safety culture messages and initiatives, and in some sites, integrate diversity and inclusion programs as well.
to be active and connected to one another.
I O N For more than our company’s business with a deep sense of responsibility to all of our stakeholders.
We provide details about our code of business conduct, our compliance management systems, and our training programs—all of which reinforce ethical behavior and help avoid corruption and other unacceptable activities.
This section also highlights our efforts to be more transparent about our operations, including our clinical trials, educational grants, and payments we make to physicians.
\| P A G E At Lilly, our policies, our code of business conduct (which we call The Red Book), our compliance management systems, our training programs, and our communications work together to reinforce ethical behavior.
We train all of our employees in ethical business practices and have systems in place to detect potential violations of the law and company policies, as well as to correct processes to avoid errors going forward.
And, we have expanded and centralized our anti-corruption due diligence work to focus on greater consistency across the globe.
by the senior vice president of enterprise risk management, who is also Lilly’s chief ethics and compliance officer.

Through decreased our emissions intensity by 12.7 percent compared to our 2012 baseline.

Total energy consumption was flat compared to improved by 0.7 percent.

Since largest energy-consuming sites—representing nearly 88 percent of our total energy consumption—increased production, in turn increasing their overall energy use per square foot of space.

In combined heat and power system at our Puerto Rico facility.

Since then, Lilly has completed initial design, with major construction expected to begin in 2019.

This project is expected to result in roughly $and approximately 15 to 20 percent reduction in GHG emissions for our Puerto Rico facility.

We also operate combined heat and power systems in Kinsale, Ireland; Sesto, Italy; and Speke, England.

Renewable Energy We will continue to evaluate further use of renewable energy to diversify our energy sources, decrease our GHG emissions, and lessen our energy use intensity over time.

We are members of the Rocky Mountain Institute’s Business Renewables Center and are currently evaluating the feasibility of incorporating more renewable energy sources.

WATER USE AND WASTEWATER Manufacturing operations account for the majority of the water used by Lilly.

In CDP’s water program, above the average for Biotech, Health Care and Pharmaceutical sector rankings.

In phosphorus emissions in our wastewater discharge by 15 percent by 2020, as compared to our 2014 baseline.

In our total wastewater phosphorus emissions declined to approximately 83 metric tonnes, a 34.4 percent decrease from 2014.

With regard to our goal progress, we have successfully surpassed our reduction goal at the end of 2018.

As a result, we are setting a stretch goal to reduce an additional of phosphorus emissions by 2020 using 2018 as the new baseline year.

We have significant source reduction projects planned, including phasing out and replacing selected cleaning agents with non-phosphorus- based alternatives.

In an increase of just under four percent from 2012, due primarily to production changes.

Lilly generates both nonhazardous and hazardous waste from its manufacturing processes.

In improvement in waste efficiency by 2020, as compared to our 2012 baseline.

We also aim to increase our recycling rate above below 10 percent of our total waste generated.

Lilly generated material directly reused) in 2018, representing a decrease of 28 percent compared to 2012, and a 30 percent decrease compared to 2017 amounts.

We were able to designate much of it as fertilizer.

With regard to progress toward our goal, we have successfully surpassed our improvement target, as our waste efficiency improved by 34 percent between 2012 and the end of 2018.

Our recycling rate increased in 47 percent in 2012, and we sent 21 percent of our waste to landfills, compared to 28 percent waste sent to landfill in 2012.

As we have successfully achieved the waste efficiency aspect of our we will focus primarily on achieving our recycling and waste-to-landfill targets.

OUR OPERATIONS We established the Energy, Waste and Water Reduction Fund in overall environmental impacts.

Since has invested more than $45.5 million in this fund, enabling the implementation of 174 projects, which all told, garnered more than $22 million in savings.

These projects collectively save more than one trillion BTUs of energy annually, avoiding more than tonnes of GHG emissions each year, measured as carbon dioxide equivalents (CO2e).

| P A G E 1 Data may be revised compared to prior reports due to changes in calculation methodology and other factors.

emission factors for landfilled and land-applied waste, and assumes transportation related emissions only for certain land-applied organic waste types.

6 Data includes energy from combustion of coal, fuel oil, natural gas, and liquid propane. 7 Data includes energy from purchased electricity, steam, and chilled water.

regulatory actions or requirements (e.g., remediation activities where the water is not used for another purpose).

for the purpose of lowering the groundwater table(s) to maintain the physical and structural integrity of building foundations.

intake not included in other water intake subcategories.

sales and marketing offices unless they are co-located at a Lilly manufacturing or research facility.

that resulted in damage to the environment (i.e., human health, aquatic life, or wildlife) or a material event requiring reporting to the U.S. Securities and Exchange Commission.

This data includes that of Lilly’s former subsidiary, Elanco Animal Health, including the period immediately following Elanco’s IPO, approximately the fourth quarter of 2018.

A G E Supply Chain We rely on our suppliers—including those who supply us with materials for research and development, active pharmaceutical ingredients (APIs), and other contract manufacturers—to ensure the availability of our human and animal medicines.

This includes our ongoing work as part of the Pharmaceutical Supply Chain Initiative (PSCI), a non-profit business membership organization founded in Lilly as one of its inaugural members.

GOVERNANCE OF SUPPLY CHAIN AT LILLY PSCI, with its member companies, created and maintain the Pharmaceutical Industry Principles for Responsible Supply Chain Management (the PSCI Principles).

The PSCI Principles provide our industry with consistent supplier performance standards in the areas of ethics, labor, health and safety, the environment, and related management systems.

contract manufacturing services Lilly manufacturing procurement contracts ask that suppliers support the PSCI Principles and conform to the HSE expectations outlined in our Supplier Code of Business Conduct.

For more than a decade, Lilly HSE professionals have worked to assess and strengthen performance at the external research laboratories and contract manufacturing organizations (CMOs) with which we do business.

In conducted onsite audits at 33 CMO sites.

OTHER SUPPLIER EDUCATION AND ENGAGEMENT Lilly is an active PSCI member and our HSE professionals have led or participated in a number of PSCI sponsored webinars and in-country events.

In professionals participated in supplier capability training in China and India, building on work in 2017 conducting third-party auditor training.

A G E Packaging and Transportation We consider many factors in selecting product packaging, including sustainability considerations, such as materials use and recyclability.

Additionally, we have achieved GHG emission reductions by changing the shipping mode for some of our pharmaceutical products from air to ocean.

Another benefit of ocean shipping is an overall reduction in packaging used because less protective packaging is required during transport.

Lilly continues to work with customers, industry partners, and public health officials to address these product end-of-life issues.

Pharmaceuticals in the Environment (PiE) After they are used to improve human and animal health, medicines enter our natural environment through the normal biological processes of waste elimination.

Reports such as the World Health Organization’s Pharmaceuticals in Drinking Water (publications following an extensive, three-year joint study by the U.S. Environmental Protection Agency and U.S. Geological Survey on the presence of contaminants in drinking water and surface water have concluded that the concentrations of pharmaceuticals in drinking water are unlikely to have a direct impact on human health and aquatic life.

Due to the importance of PiE issues to Lilly and our stakeholders, we have established a PiE Governance Committee that reports to our executive-level Global HSE Committee.

| P A G E pharmaceutical discharges from manufacturing sites, our Lilly Aquatic Exposure Guideline (LAEG) program.

residues in water, in collaboration with the U.S.

About Elanco Animal Health In September offering of Elanco, thereby making it an independently traded company.

Elanco provides comprehensive products and knowledge services to improve the health of food animals and pets in more than the world.

Antibiotics, including those manufactured by Elanco, are one way, but not the only way, that farmers keep their animals healthy.

Elanco Animal Health has updated its commitment to fighting antimicrobial resistance, which includes promoting responsible antibiotic use practices and policies while developing alternatives to medically important antibiotics (a subset of which include critically important antibiotics to human health).

ELANCO’S ANTIBIOTIC STEWARDSHIP PLAN The Antimicrobial Resistance Challenge, led by the Centers for Disease Control and Prevention (CDC) and U.S. Health and Human Services (HHS), is a yearlong effort to accelerate the fight against antimicrobial resistance with action across governments and industries.

Elanco’s commitment—outlined within the CDC’s Antimicrobial Resistance Challenge materials—is the next step in its eight-point antibiotic stewardship plan.

It is of utmost importance we address the complex challenge of antimicrobial resistance and preserve the effectiveness of medicines for people and animals.

Supporting the CDC and HHS effort is an important step in reaffirming our commitment to responsible antibiotic usage and veterinary oversight capacity around the world.

A G E Lilly focuses on creating a companywide culture where best-in-class safety practices are intuitively and consistently followed.

We have found that tracking leading—or predictive indicators—such as ergonomic risk, safety culture surveys, and vehicle safety training contributes greatly to our company safety culture.

Since we introduced our global safety goals in percent, equivalent to the prevention of hundreds of injuries and illnesses to Lilly employees across the globe.

In established new goals for the three occupational safety metrics we track: recordable injuries, lost-time injuries, and motor vehicle collision rate.

In influence behavior change and reduce company injury and illness rates.

We know that to reach our goals for safety performance, Lilly must continue to instill and promote a best-in-class safety culture.

While the most common work-related injuries are covered by our safety programs, we also have committed to systematically address infrequent but severe events, where the consequences can be potentially life-altering or fatal.

business processes In we created a global SIF team responsible for analyzing potential SIF events and precursors.

The SIF team analyzes event data, always focusing on reducing the probability of employees’ exposure to high-risk hazards.

2018 15% 2017 15% 2016 16% 2015 16% 2007 25% 1 Refers to non-motor vehicle injuries resulting in abrasion, contusion, and laceration.

| P A G E Sales and Marketing Safety At Lilly, sales and marketing employees represent approximately 35 percent of our global workforce.

In motor vehicle safety program, HSEDirections, designed specifically for the thousands of Lilly employees who are on the road every day, visiting physicians, hospitals, clinics, and other customers.

effect it can have on individuals and their loved ones.

We work to foster a healthy, vibrant work environment, while also supporting our people in the important time that they spend at home, with their families, and in their communities.

At Lilly, we take a broad view of well-being that emphasizes multiple dimensions of each employee’s life.

While local cultures, regulations, and market dynamics influence our offerings in each country, our employee well-being strategy is global.

R A M A healthy workplace is one where employees and managers collaborate on processes to protect and promote the health, safety, and well-being of everyone.

Your social network can offer support, happiness, contentment, a sense of belonging, and can help during difficult times.

In the United States, our myBestLife program offers a set of tools and resources to help employees better manage their health, as well as identify those things that can help individuals live a healthier and more active life.

Lilly offers health plan coverage to employees and their eligible dependents, and our coverage for preventive health services go well beyond the requirements established under federal healthcare reform.

We partner with our food service vendors to offer a wide range of healthier dining choices and snacks—some of which are subsidized by Lilly.

We provide showers and bike racks for the more than by bicycle.

Other efforts to support our employees’ physical and emotional health in the United States include access to a dietitian, frequent fitness challenges, and a comprehensive employee assistance program.

Across the United States, we have also designated all sites smoke-free.

New parents are eligible for a generous parental leave, two on-site child development centers at corporate headquarters, back-up care options, and parenting education opportunities.

New mothers receive maternity leave benefits and access to lactation rooms.

We promote financial well-being through a variety of online financial tools and financial advisory programs, and we offer individual financial counseling on-site or by phone.

WELLNESS IN OUR INTERNATIONAL SITES Lilly affiliate sites around the world offer extensive wellness programs, aimed at providing a holistic approach to employee health, safety, and well-being.

These integrated programs feature safety culture messages and initiatives, and in some sites, integrate diversity and inclusion programs as well.

to be active and connected to one another.

I O N For more than our company’s business with a deep sense of responsibility to all of our stakeholders.

We provide details about our code of business conduct, our compliance management systems, and our training programs—all of which reinforce ethical behavior and help avoid corruption and other unacceptable activities.

This section also highlights our efforts to be more transparent about our operations, including our clinical trials, educational grants, and payments we make to physicians.

| P A G E At Lilly, our policies, our code of business conduct (which we call The Red Book), our compliance management systems, our training programs, and our communications work together to reinforce ethical behavior.

We train all of our employees in ethical business practices and have systems in place to detect potential violations of the law and company policies, as well as to correct processes to avoid errors going forward.

And, we have expanded and centralized our anti-corruption due diligence work to focus on greater consistency across the globe.

by the senior vice president of enterprise risk management, who is also Lilly’s chief ethics and compliance officer.